IMMT-DT: A Potential Drug Target (G148645)

Target Name: ICMT-DT

NCBI ID: G148645

ICMT-DT

Other Name(s): C1orf211 | LINC00337 | ICMT divergent transcript | NCRNA00337

IMMT-DT: A Potential Drug Target

ICMT-DT, also known as C1orf211, is a protein that is expressed in various tissues throughout the body. It is a member of the IMMU-like 1 (IML1) family, which is known for its role in the regulation of inflammation and immune responses.

ICMT-DT has been shown to play a role in the development and progression of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its functions include regulating the activity of immune cells, promoting the recruitment of immune cells to sites of infection or injury, and modulating the response of cancer cells to chemotherapy.

In addition to its potential role in disease, ICMT-DT has also been shown to have potential as a drug target. Its unique structure and the fact that it is expressed in multiple tissues make it an attractive target for researchers to study.

One of the main reasons for its potential as a drug target is its unique structure. ICMT-DT has a molecular weight of 42 kDa and consists of 116 amino acids. It has a distinct N-terminus, which is known as the N-tail , and a C-terminus that is involved in its interactions with other proteins.

The N-tail of ICMT-DT contains a unique feature known as a conserved domain. This domain is composed of 20 amino acids and is located at the center of the molecule. It is thought to play a role in the stability and stability of the ICMT-DT molecule, and it may also be involved in its interactions with other proteins.

Another reason why ICMT-DT is an attractive drug target is its location in the body. It is expressed in various tissues throughout the body, including the brain, spleen, and Peyer's patches. This makes it an attractive target for drugs that can target it specifically in these tissues.

In addition to its potential as a drug target, ICMT-DT has also been shown to have potential as a biomarker. Its expression has been shown to be elevated in various diseases, including cancer, and it has been used as a biomarker to predict the outcomes of certain therapies.

One of the main challenges in studying ICMT-DT as a drug target is its complexity. Its unique structure and the fact that it is expressed in multiple tissues make it difficult to study. However, researchers are working to overcome these challenges and to understand its potential as a drug target.

In conclusion, ICMT-DT is a protein that has the potential to be a drug target due to its unique structure and its location in the body. Its functions in the regulation of inflammation and immune responses make it an attractive target for researchers to study. Further research is needed to understand its potential as a drug target and as a biomarker.

Protein Name: ICMT Divergent Transcript

The "ICMT-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ICMT-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets